PHI with Peritoneal cancer
How does this condition affect your private health insurance?
Peritoneal cancer, or Peritonealkrebs, is a rare and aggressive cancer that originates in the peritoneum, the membrane lining the abdominal cavity and covering the abdominal organs. It behaves similarly to advanced ovarian cancer but arises directly from peritoneal cells, rather than spreading from another organ. Symptoms are often vague and can include abdominal swelling, pain, bloating, nausea, and changes in bowel habits, leading to late diagnosis. This cancer spreads rapidly across the peritoneal surface, forming tumors that can obstruct organs. Treatment typically involves extensive surgery (cytoreductive surgery) often combined with hyperthermic intraperitoneal chemotherapy (HIPEC), followed by systemic chemotherapy. Prognosis is generally poor due to its aggressive nature and late detection.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months for initial diagnosis, treatment, and recovery from surgery and chemotherapy.
Duration of Illness (Lifetime)
Often chronic and recurrent; many patients experience remission followed by relapse, requiring ongoing management or palliative care.
Cost of Treatment (Initial)
Very high (e.g., €50,000 - €200,000+) due to complex surgical procedures (cytoreductive surgery with HIPEC), extensive hospital stays, and expensive systemic chemotherapy.
Cost of Treatment (Lifetime)
Extremely high (e.g., €100,000 - €500,000+) due to potential for recurrence, repeated treatments, palliative care, and management of complications.
Mortality Rate
High (e.g., 60-80% within 5 years, depending on stage and response to treatment).
Risk of Secondary Damages
High (e.g., >70%). Secondary damage includes bowel obstruction, ascites, severe pain, malnutrition (cachexia), kidney failure, and significant side effects from aggressive chemotherapy and surgery. Psychological distress is also common.
Probability of Full Recovery
Low (e.g., <20% for long-term, disease-free survival), as recurrence is common even after extensive treatment, particularly for advanced stages.
Underlying Disease Risk
Moderate to high (e.g., 30-50%). Can be associated with genetic mutations (e.g., BRCA1/BRCA2), a history of ovarian or breast cancer, or other gastrointestinal malignancies. It may also occur de novo (primary peritoneal cancer) without an obvious underlying primary tumor.